What frontline treatment would you offer a patient with AITL who is not a candidate for an anthracycline due to baseline cardiomyopathy?

I would probably offer this patient CEOP. No data to back this up, however. Incorporation of etoposide in addition to CHOP confers a progression-free survival advantage in younger patients with PTCL, so it's reasonable to assume the etoposide would have activity.